Riskpilot← Back to searchSign inGet full accessAristo Pharma Nordic ApS
APSActiveCVR 32328768Tonsbakken 16, 2.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20112 employeeswww.amnealnordic.com
Revenue 2025
DKK 453K
-14% vs 2024
EBITDA margin
5.7%
-20% vs 2024
Equity ratio
6.2%
Financial strength
Net profit 2025
DKK 22K
-14% vs 2024
| Revenue | DKK 453K | -14% |
| EBITDA | DKK 26K | -20% |
| Net profit | DKK 22K | -14% |
| Total assets | DKK 3M | +21% |
| Equity | DKK 185K | +13% |
| Employees | 2 | — |
Legal name
Aristo Pharma Nordic ApS
CVR number
32328768
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8. februar 2011
Share capital
DKK 107.250
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem i forening med en direktør eller af 2 bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at sælge kvalitetslægemidler til apoteker i de nordiske lande samt hermed beslægtet virksomhed.
Address
Tonsbakken 16, 2.
Phone
+4570707982
Email
info.nordic@aristo-pharma.dk
Website
www.amnealnordic.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -297 | -589 | -734 | 145 | -475 | -3.907 | -949 | 470 | 805 | 789 | 717 | 327 | 529 | 453 |
| Staff expenses | -227 | -983 | -749 | -921 | -1.237 | -954 | -760 | -598 | -692 | -721 | -657 | -296 | -331 | -289 |
| EBITDA | -524 | -1.572 | -1.483 | -776 | -1.712 | -4.860 | -1.708 | -128 | 114 | 68 | 60 | 31 | 33 | 26 |
| Depreciation & amort. | -28 | -216 | -150 | -257 | -66 | -27 | -9 | -3 | -6 | -3 | -3 | -3 | -2 | -1 |
| EBIT | -552 | -1.788 | -1.633 | -1.033 | -1.778 | -4.887 | -1.718 | -132 | 108 | 66 | 57 | 28 | 30 | 25 |
| Net financials | -18 | -111 | -36 | -569 | -292 | -127 | -158 | -155 | -45 | -20 | -5 | -3 | -5 | -4 |
| Profit before tax | -285 | -1.898 | -1.669 | -1.602 | -2.070 | -5.014 | -1.876 | -286 | 62 | 45 | 52 | 26 | 25 | 22 |
| Tax | 143 | -123 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -428 | -1.776 | -1.669 | -1.602 | -2.070 | -5.014 | -1.876 | -286 | 62 | 45 | 52 | 26 | 25 | 22 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.516 | 4.420 | 3.437 | 3.222 | 6.211 | 6.778 | 3.004 | 760 | 332 | 495 | 1.376 | 1.957 | 2.466 | 2.988 |
| Equity | -484 | -1.769 | -1.059 | -2.661 | -4.731 | -1.174 | -3.050 | -1.336 | -1.274 | 61 | 112 | 138 | 163 | 185 |
| Long-term debt | 0 | 0 | 0 | 4.880 | 9.346 | 2.000 | 5.150 | 1.367 | 1.276 | 397 | 1.086 | 1.765 | 2.233 | 2.737 |
| Short-term debt | 2.000 | 6.188 | 4.496 | 1.004 | 1.596 | 5.786 | 738 | 570 | 228 | 37 | 178 | 54 | 70 | 66 |
| Total debt | 2.000 | 6.188 | 4.496 | 5.884 | 10.942 | 7.786 | 5.888 | 1.936 | 1.504 | 435 | 1.264 | 1.819 | 2.302 | 2.803 |
EBITDA margin
5.7%
This company
15.8%
Market median
-64% vs market
20122025
Equity ratio
6.2%
This company
38.2%
Market median
-84% vs market
20122025
Return on equity
11.7%
This company
18.4%
Market median
+36% vs market
20122025
Net profit margin
4.8%
This company
8.1%
Market median
-41% vs market
20122025
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20122025
Debt / equity
15.16×
This company
0.62×
Market median
-2345% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JV Management | Management | 2016 | — | — |
PL Management | Management | 2011 | — | — |
LS Management | Management | 2015 | — | — |
SA Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
KP Management | Management | 2021 | — | — |
HN Management | Management | 2017 | — | — |
SR Management | Management | 2022 | — | — |
JM Management | Management | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2015 | — | — | |
| Chairman | 2019 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2014 | — | — | |
| Chairman | 2017 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2017 | |
| Individual | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aristo Pharma Nordic ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| János Váczi | Management | 0 companies |
| Peter Lassen | Management | 0 companies |
| Lena Storm Christensen | Management | 0 companies |
| Svend Aage Johansen | Chief Executive Officer | 0 companies |
| Kenneth Pedersen | Management | 0 companies |
| Hasnain Nasir Butt | Management | 0 companies |
| Sascha Rauschke | Management | 0 companies |
| John Morell Frellsen | Management | 0 companies |
| János Váczi | Board of Directors | 0 companies |
| Robert Maciej Szymanski | Board of Directors | 0 companies |
| Chirag K Patel | Chairman | 0 companies |
| Christian Jaaks | Chairman | 0 companies |
| John Hudson Kriwet | Chairman | 0 companies |
| Peter Prock | Board of Directors | 0 companies |
| Jannes Paul Beeskow | Board of Directors | 0 companies |
| Joseph Todisco | Board of Directors | 0 companies |
| Chintu Patel | Board of Directors | 0 companies |
| János Váczi | Chairman | 0 companies |
| Anton Alwin Karremann | Chairman | 0 companies |